Due to proven upregulation in an ex-vivo setting, CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT has entered the clinical arena for assessing sites of disease in patients with varying neoplasms, including hematological malignancies, solid tumors or benign pathologies [9, 16, 17]. This evidence concerns the gene CXCR4 and neoplasm.